GRAIL (NASDAQ:GRAL) Shares Climb 6% - What's Next?

GRAIL logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GRAIL shares rose 6% to about $108.25, while midday trading volume was 88% below its average.
  • Analysts’ views are mixed: five rate the stock Buy, six Hold, and one Sell. The consensus rating is Hold, with an average price target of $128.80.
  • Quarterly results beat the earnings-per-share estimate, reporting a loss of $2.21 per share versus an expected loss of $2.45, but revenue of $37.53 million fell short of the $44.21 million consensus.
  • Interested in GRAIL? Here are five stocks we like better.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) traded up 6% on Thursday. The stock traded as high as $110.59 and last traded at $108.2520. 110,969 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 961,897 shares. The stock had previously closed at $102.10.

Analysts Set New Price Targets

Several brokerages recently commented on GRAL. Weiss Ratings reiterated a "sell (d-)" rating on shares of GRAIL in a report on Thursday, October 15th. UBS Group increased their price objective on shares of GRAIL from $105.00 to $175.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. Royal Bank Of Canada lifted their price objective on shares of GRAIL from $84.00 to $100.00 and gave the company a "sector perform" rating in a research note on Thursday, November 5th. Mizuho upped their price objective on shares of GRAIL from $65.00 to $100.00 and gave the company a "neutral" rating in a research report on Friday, September 25th. Finally, Robert W. Baird raised their price target on shares of GRAIL from $96.00 to $118.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 22nd. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $128.80.

Get Our Latest Report on GRAIL

GRAIL Trading Up 4.1%

The stock has a market cap of $4.78 billion, a P/E ratio of -11.21 and a beta of 2.86. The firm's 50-day simple moving average is $122.99 and its 200 day simple moving average is $79.79.

GRAIL (NASDAQ:GRAL - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.45) by $0.24. GRAIL had a negative return on equity of 16.13% and a negative net margin of 243.80%. The firm had revenue of $37.53 million for the quarter, compared to the consensus estimate of $44.21 million. On average, analysts anticipate that GRAIL, Inc. will post -9.11 EPS for the current year.

Insider Buying and Selling

In other GRAIL news, insider Andrew Partridge sold 7,873 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $1,152,528.47. Following the completion of the sale, the insider directly owned 155,865 shares of the company's stock, valued at approximately $22,817,077.35. This represents a 4.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Aaron Freidin sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $107.62, for a total transaction of $322,860.00. Following the sale, the chief financial officer owned 222,364 shares of the company's stock, valued at $23,930,813.68. The trade was a 1.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 132,944 shares of company stock valued at $15,155,665 over the last quarter. Corporate insiders own 1.83% of the company's stock.

Hedge Funds Weigh In On GRAIL

Hedge funds and other institutional investors have recently modified their holdings of the stock. Moody National Bank Trust Division grew its position in shares of GRAIL by 1.3% in the third quarter. Moody National Bank Trust Division now owns 13,478 shares of the company's stock valued at $1,889,000 after purchasing an additional 178 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in shares of GRAIL by 110.9% in the third quarter. SBI Securities Co. Ltd. now owns 388 shares of the company's stock valued at $54,000 after purchasing an additional 204 shares in the last quarter. North Star Investment Management Corp. lifted its holdings in shares of GRAIL by 809.1% during the 3rd quarter. North Star Investment Management Corp. now owns 300 shares of the company's stock worth $42,000 after acquiring an additional 267 shares during the period. GAMMA Investing LLC lifted its stake in GRAIL by 30.3% during the third quarter. GAMMA Investing LLC now owns 1,273 shares of the company's stock worth $178,000 after purchasing an additional 296 shares during the period. Finally, Root Financial Partners LLC bought a new position in shares of GRAIL during the 3rd quarter worth approximately $44,000.

About GRAIL

(Get Free Report)

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL's flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GRAIL Right Now?

Before you consider GRAIL, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.

While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines